1. Home
  2. News
  3. Neurotech International Ltd.
  4. Positive Genomic Effects of NTI164 in PANDAS/PANS Patients
More Neurotech International Ltd. news
Neurotech International Ltd.ASX: NTI

Positive Genomic Effects of NTI164 in PANDAS/PANS Patients

Nov 14, 2024 at 9:41 PM EST · Issued by Neurotech International Ltd.

Filed with ASX · Nov 14, 2024 at 9:41 PM EST · 3 pages · English

On 6ix: 6ix.com/news/positive-genomic-effects-of-nti164-in-pandaspans-patients

Neurotech International Ltd. on 6ix

Story so far

  • Further clinical benefit at 52 weeks in PANDAS/PANS patientsJun 6, 2024
  • PANDAS/PANS Patients Show Continued Clinical ImprovementFeb 21, 2024

Earlier from Neurotech International

  • Neurotech Appoints Dr Anthony Filippis as MD/CEONov 10, 2024
  • US FDA Response to Orphan Drug Request in PANDAS/PANSOct 3, 2024
  • NTI164 Reverses Immune Dysregulation in PANDAS/PANS ChildrenSep 8, 2024
  • Neurotech Global Partnering and Registration StrategyAug 11, 2024
  • Further Significant Improvement in Rett Syndrome PatientsJul 30, 2024

Later from Neurotech International

  • NTI Receives Ethics Approval to Commence Human PK StudyNov 24, 2024
  • Neurotech Receives US ODD in Rett SyndromeNov 25, 2024
  • Neurotech Receives $2.44 Million R&D Tax Incentive RefundJan 30, 2025
  • NTI Signs Development Agreement for Cannabinoid TherapiesFeb 12, 2025
  • Positive Opinion on OMPD for NTI164 in EuropeFeb 27, 2025
All Neurotech International news releases↗

Follow Neurotech International into a list and get an email when it puts out news.

Follow Neurotech International
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer